Ask AI
ProCE Banner Events

Share

ROS1 Revealed: A Cancer Conversation on the Changing Tide of NSCLC Treatment

Expert discussions and takeaways for the evolving treatment landscape for ROS1-altered NSCLC.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for oncologists and other healthcare professionals caring for patients with non-small-cell lung cancer.

Time and location

Wednesday, August 21, 2024

8:30 AM - 9:45 AM Eastern Time (ET)

Virtual

Agenda

ROS1-Rearranged NSCLC

Introduction and ARS Questions

I. Biology and Clinical Background of ROS1

  • Mechanism of ROS1 gene fusions in NSCLC
  • Common ROS1 genetic translocations in NSCLC

II. Optimizing Biomarker Testing for ROS1+ NSCLC

  • NGS, FISH, IHC, liquid biopsies, gene-fusion assessment
  • Addressing conflicting pathologic results (IHC+ /FISH-neg result?

III. Available/Emerging Clinical Data for ROS1+ NSCLC

  • NCCN recommendations for the treatment of ROS1-altered NSCLC
  • Disease and patient-specific factors informing treatment of choice
  • Overview of other novel investigational agents in ROS1-altered NSCLC

IV. Overcoming Disparities in Patients With ROS1+ NSCLC

  • Key areas of improvement: biomarker testing for racial and ethnic underrepresented communities
  • Strategies for improving health disparities in ROS1+ NSCLC care

Closing Remarks and Question and Answer Session

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimize treatment for patients with ROS1-altered NSCLC. 

Target Audience
This program is intended for oncologists and other healthcare professionals caring for patients with non-small-cell lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Demonstrate a clear understanding of the biology, pathophysiology, and epidemiology surrounding ROS1 mutations and resistance mechanisms limiting frontline therapy effectiveness in NSCLC
  • Incorporate optimal molecular testing strategies and interpretation to identify patients who may benefit from newly approved or rapidly emerging targeted therapies for ROS1-altered NSCLC
  • Evaluate current and emerging clinical trial data regarding the safety and efficacy of newly approved or emerging next-generation TKIs, with a consideration for future treatment plans in ROS1-positive NSCLC
  • Summarize the sources and rational solutions to health disparities that are leading to disproportionate care among racial and ethnic minority patients with NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol-Myers Squibb.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.